News & Updates

Show Multimedia Only

Testosterone replacement therapy boosts sexual, physical function after radical prostatectomy

22 May 2026 by

In men with hypogonadism who have undergone radical prostatectomy for low-grade prostate cancer, testosterone replacement therapy (TRT) helps improve sexual and physical function, according to the SPIRIT study.

Testosterone replacement therapy boosts sexual, physical function after radical prostatectomy

22 May 2026

Which medications actually work for chronic migraine?

22 May 2026

Several calcitonin gene-related peptide-targeted therapies show potential efficacy for the treatment of chronic migraine, suggest the results of a systematic review.

Which medications actually work for chronic migraine?

22 May 2026

Novel neuroplastogen for PTSD clears phase 2 trial

22 May 2026

The highly selective, rapid-acting neuroplastogen TSND-201 appears to be efficacious and well tolerated in the treatment of post-traumatic stress disorder (PTSD), according to the results of a phase 2 trial.

Novel neuroplastogen for PTSD clears phase 2 trial

22 May 2026

Guselkumab shows efficacy in perianal fistulizing Crohn’s disease

22 May 2026 by

Treatment with guselkumab resulted in significantly higher rates of combined fistula remission at week 24 in adults with active perianal fistulizing Crohn’s disease (PFCD) compared with placebo, according to the FUZION trial presented at DDW 2026.

Guselkumab shows efficacy in perianal fistulizing Crohn’s disease

22 May 2026

Is 3-month DAPT noninferior to 1-year strategy in CABG patients?

21 May 2026 by

Treatment with dual antiplatelet therapy (DAPT) for 3 months is as good as the 12-month DAPT strategy in saphenous vein graft (SVG) occlusion but is more efficacious in reducing the risk of bleeding among patients undergoing elective coronary artery bypass grafting (CABG), a study has shown.

Is 3-month DAPT noninferior to 1-year strategy in CABG patients?

21 May 2026

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

21 May 2026 by

Results from the phase III TRIUMpH-EE study demonstrate the superiority of the novel potassium-competitive acid blocker (P-CAB) tegoprazan over the proton pump inhibitor (PPI) lansoprazole in providing faster healing of erosive esophagitis (EE) and heartburn relief.

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

21 May 2026

Methylphenidate may be safely used in patients with MDD

21 May 2026

Use of methylphenidate in adult patients with major depressive disorder (MDD) appears to be safe, being associated with reduced hospitalization or emergency visits without increasing the risk of suicidality, mania, or recurrence, according to a retrospective study.

Methylphenidate may be safely used in patients with MDD

21 May 2026

Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC

21 May 2026 by

Treatment with gedatolisib plus fulvestrant, with or without palbociclib, significantly improves progression-free survival (PFS) in patients with HR+/HER2– PIK3CA wild-type (WT) advanced breast cancer (ABC) compared with fulvestrant alone, according to the VIKTORIA-1 trial presented at ESMO Breast Cancer 2026.

Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC

21 May 2026

Aspirin mitigates preterm birth risk linked to heat exposure

20 May 2026

Initiating low-dose aspirin early in pregnancy may reduce the risk of preterm birth associated with heat exposure among nulliparous women, according to a study.

Aspirin mitigates preterm birth risk linked to heat exposure

20 May 2026

Response-adapted chemo-free adjuvant treatment feasible in low-risk HER2+ early breast cancer

20 May 2026 by

A neoadjuvant pathologic complete response-adapted de-escalation strategy to omit chemotherapy in the adjuvant setting is clinically feasible and helps preserve health-related quality of life in highly selected patients with low-risk HER2-positive early breast cancer, according to the phase II PHERGain-2 trial.

Response-adapted chemo-free adjuvant treatment feasible in low-risk HER2+ early breast cancer

20 May 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Testosterone replacement therapy boosts sexual, physical function after radical prostatectomy

Testosterone replacement therapy boosts sexual, physical function after radical prostatectomy

Which medications actually work for chronic migraine?

Which medications actually work for chronic migraine?

Novel neuroplastogen for PTSD clears phase 2 trial

Novel neuroplastogen for PTSD clears phase 2 trial

Guselkumab shows efficacy in perianal fistulizing Crohn’s disease

Guselkumab shows efficacy in perianal fistulizing Crohn’s disease

Is 3-month DAPT noninferior to 1-year strategy in CABG patients?

Is 3-month DAPT noninferior to 1-year strategy in CABG patients?

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

Methylphenidate may be safely used in patients with MDD

Methylphenidate may be safely used in patients with MDD

Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC

Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC

Aspirin mitigates preterm birth risk linked to heat exposure

Aspirin mitigates preterm birth risk linked to heat exposure

Response-adapted chemo-free adjuvant treatment feasible in low-risk HER2+ early breast cancer

Response-adapted chemo-free adjuvant treatment feasible in low-risk HER2+ early breast cancer